ABSTRACT
Continuous risk of recurrence scores (CRS) based on tumor gene expression are vital prognostic tools for breast cancer (BC). Studies have shown that Black women (BW) have higher CRS than White women (WW). Although systemic injustices contribute substantially to BC disparities, evidence for biological and germline contributions is emerging. We investigated germline genetic associations with CRS and CRS disparity using approaches modeled after transcriptome-wide association studies (TWAS). In the Carolina Breast Cancer Study, using race-specific predictive models of tumor expression from germline genetics, we performed race-stratified (N=1,043 WW, 1083 BW) linear regressions of three CRS (ROR-S: PAM50 subtype score; Proliferation Score; ROR-P: ROR-S plus Proliferation Score) on imputed Genetically-Regulated tumor eXpression (GReX). Using Bayesian multivariate regression and adaptive shrinkage, we tested GReX-prioritized genes for associations with PAM50 tumor expression and subtype to elucidate patterns of germline regulation underlying GReX-CRS associations. At FDR-adjusted P < 0.10, we detected 7 and 1 GReX-prioritized genes among WW and BW. Among WW, CRS were positively associated with MCM10, FAM64A, CCNB2, and MMP1 GReX and negatively associated with VAV3, PCSK6, and GNG11 GReX. Among BW, higher MMP1 GReX predicted lower Proliferation score and ROR-P. GReX-prioritized gene and PAM50 tumor expression associations highlighted potential mechanisms for GReX-prioritized gene to CRS associations. Among BC patients, we find differential germline associations with CRS by race, underscoring the need for larger, diverse datasets in molecular studies of BC. Our findings also suggest possible germline trans-regulation of PAM50 tumor expression, with potential implications for CRS interpretation in clinical settings.
SIGNIFICANCE We find race-specific genetic associations with breast cancer risk-of-recurrence scores (CRS). Follow-up analyses suggest mediation of these associations by PAM50 molecular subtype and gene expression, with implications for clinical interpretation of CRS.
Competing Interest Statement
CMP is an equity stock holder, consultant, and board of directors member of BioClassifier LLC and GeneCentric Diagnostics. CMP is also listed as an inventor on patent applications on the Breast PAM50 assay.
Funding Statement
This work was supported by Susan G. Komen for the Cure for CBCS study infrastructure. Funding was provided by the National Institutes of Health, National Cancer Institute P01-CA151135, P50-CA05822, and U01-CA179715 to AFO, CMP, and MAT. AP is supported by T32ES007018. MIL is supported by R01-HG009937, R01-HG009937, R01-MH118349, P01-CA142538, and P30-ES010126. The Translational Genomics Laboratory is supported in part by grants from the National Cancer Institute (3P30CA016086) and the University of North Carolina at Chapel Hill University Cancer Research Fund. Genotyping was done at the DCEG Cancer Genomics Research Laboratory using funds from the NCI Intramural Research Program. Funding for BCAC and iCOGS came from Cancer Research UK [grant numbers C1287/A16563, C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565], the European Union's Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST respectively), the European Community's Seventh Framework Programme under grant agreement n 223175 [HEALTHF2-2009-223175] (COGS), the National Institutes of Health [CA128978] and Post-Cancer GWAS initiative [1U19 CA148537, 1U19 CA148065-01 (DRIVE) and 1U19 CA148112 - the GAME-ON initiative], the Department of Defence [W81XWH-10-1-0341], and the Canadian Institutes of Health Research CIHR) for the CIHR Team in Familial Risks of Breast Cancer [grant PSR-SIIRI-701]. All studies and funders as listed in Michailidou K et al (2013 and 2015) and in Guo Q et al (2015) are acknowledged for their contributions.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Office of Human Research Ethics at the University of North Carolina at Chapel Hill, and informed consent was obtained from each participant.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
CONFLICT OF INTEREST STATEMENT CMP is an equity stock holder, consultant, and board of directors member of BioClassifier LLC and GeneCentric Diagnostics. CMP is also listed as an inventor on patent applications on the Breast PAM50 assay. The other authors declare no potential conflicts of interest.
Additional analyses across ancestry and race with contextualization for biological results
Data Availability
Expression data from CBCS is available on NCBI GEO with accession number GSE148426. CBCS genotype datasets analyzed in this study are not publicly available as many CBCS patients are still being followed and accordingly CBCS data is considered sensitive; the data is available from M.A.T upon reasonable request. Supplementary Data includes summary statistics for eQTL results, tumor expression models, and relevant R code for training expression models in CBCS and are freely available at https://github.com/bhattacharya-a-bt/CBCS_TWAS_Paper/. R code for analyses provided in this paper are available at https://github.com/APUNC/CBCS---Risk-of-Recurrence-Paper.
https://github.com/bhattacharya-a-bt/CBCS_TWAS_Paper/
http://bcac.ccge.medschl.cam.ac.uk/bcacdata/icogs-complete-summary-results
ABBREVIATIONS
- BW
- Black Women
- CBCS
- Carolina Breast Cancer Study
- CRS
- Continuous Risk of recurrence Score
- eQTL
- expression Quantitative Trait Locus
- ER
- Estrogen Receptor
- FDR
- False Discovery Rate
- GReX
- Genetically-Regulated tumor eXpression
- GWAS
- Genome-Wide Association Study
- HR
- Hormone Receptor
- LFSR
- Local False Sign Rate
- LumA
- Luminal A
- LumB
- Luminal B
- NC
- North Carolina
- ROR
- Risk of Recurrence
- SCC
- Subtype-Centroid Correlations
- SNP
- Single Nucleotide Polymorphism
- TCGA
- The Cancer Genome Atlas
- TWAS
- Transcriptome-Wide Association Study
- WW
- White Women
